Physician profile
Arian Gower
NPI 1639531403
$78,554.05
in general payments reported to CMS, 2019-2025
39 companies · $44K in 2025
The $44K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2021: $1,589 · 2022: $2,751 · 2023: $4,096 · 2024: $26K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Food and Beverage: $15K · Consulting Fee: $7,050 · Travel and Lodging: $5,161 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,325.00 |
| Food and Beverage | $15,246.81 |
| Consulting Fee | $7,050.00 |
| Travel and Lodging | $5,160.66 |
| Education | $268.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $56,897.07 | 2021-2025 | Krystexxa, Tavneos, Repatha |
| Advanced Instruments, LLC | $5,250.00 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $2,440.60 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $2,310.62 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $1,738.24 | 2021-2025 | |
| Horizon Therapeutics Plc | $1,648.00 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $1,061.22 | 2021-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $864.56 | 2021-2025 | Acthar, Terlivaz |
| Glaxosmithkline, LLC. | $850.38 | 2021-2025 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $704.86 | 2021-2023 | Veltassa, Korsuva |
| Alexion Pharmaceuticals, INC. | $620.28 | 2022-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $612.92 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $472.55 | 2021-2025 | Jynarque |
| Travere Therapeutics, INC. | $318.92 | 2023-2025 | Filspari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.16 | 2022-2025 | Jardiance |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $288.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $250.91 | 2021-2023 | Xarelto |
| Akebia Therapeutics INC | $244.76 | 2021-2025 | Vafseo, Auryxia |
| Lilly USA, LLC | $243.07 | 2021-2024 | Mounjaro, Jardiance |
| Lexicon Pharmaceuticals, INC. | $218.70 | 2024 | Inpefa |
| Esperion Therapeutics, INC. | $190.20 | 2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $149.87 | 2019-2023 | Eliquis, Camzyos |
| Abbvie INC. | $125.00 | 2025 | |
| Janssen Scientific Affairs, LLC | $117.89 | 2023 | Xarelto |
| Fresenius USA Marketing, INC. | $110.78 | 2023-2025 | Velphoro |
| Ani Pharmaceuticals, INC. | $103.24 | 2024-2025 | Purified Cortrophin Gel |
| Amarin Pharma, INC. | $69.61 | 2021 | |
| Ardelyx, INC. | $51.23 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $51.12 | 2019-2023 | Verquvo |
| Alnylam Pharmaceuticals INC. | $40.22 | 2023 | Onpattro |
| Apellis Pharmaceuticals, INC. | $31.40 | 2025 | |
| Scpharmaceuticals INC. | $26.31 | 2024 | |
| Sobi, INC | $25.24 | 2025 | |
| Inspire Medical Systems, INC. | $23.97 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $23.01 | 2022 | |
| Daiichi Sankyo INC. | $22.49 | 2022 | |
| Opko Pharmaceuticals, LLC | $21.82 | 2024 | Rayaldee |
| Xeris Pharmaceuticals, INC. | $18.37 | 2023 | Keveyis |
| Currax Pharmaceuticals LLC | $17.16 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arian Gower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.